Newspatrolling.com News cum Content Syndication Portal Online
Q3 results show strong momentum with 26% PAT growth in YoY-9 month backed by expansion of its anti-microbial portfolio
New Delhi, 13 February 2025: Orchid Pharma Ltd., a vertically integrated pharmaceutical company spanning the entire pharmaceutical value chain from discovery to delivery has announced its Q3 financial results for FY 2024-25, reporting a 26% year-on-year increase in Profit After Tax (PAT) in YoY-9 month.
This steady trajectory reflects the company’s strategic execution and ongoing expansion efforts, particularly in the Anti-Microbial Stewardship (AMS) division, which is poised to drive sustained momentum.
The Orchid AMS division is a key pillar of Orchid Pharma’s long-term strategy and has contributed significantly to the company’s performance. As the division continues to gain traction, it is laying a strong foundation for future scalability in the critical fight against anti-microbial resistance.
Commenting on the results, Manish Dhanuka, Managing Director, Orchid Pharma said, “We believe that our commitment to innovation and operational excellence will yield positive results. The AMS division is progressing as expected, and we are confident in its potential to drive future growth. Our focus remains on developing specialized solutions, such as our novel drug Enmetazobactam, and enhancing market reach with ORBLICEF, launched in partnership with Cipla. With a robust product pipeline and strategic R&D investments, we are well-positioned to accelerate growth in the coming quarters.”
Orchid Pharma remains dedicated to addressing global healthcare challenges through innovation, with a strong emphasis on sustainable expansion and enhanced global presence. With a pipeline of promising developments and continued operational enhancements, the company is poised for strong performance in the next phase of its growth journey.
